### ğŸ«€ Dyslipidemia: Statin Therapy in Adults â‰¥75 Years  

#### âœ… True Statements  
1. Managing dyslipidemia for the **primary prevention** of **atherosclerotic cardiovascular disease (ASCVD)** in adults **aged 75Â years and older** requires an **individualized approach**.  
2. When statin therapy is selected for patients â‰¥75Â years, a **moderateâ€‘intensity statin** is recommended, and the **expected benefit is less robust** than in younger highâ€‘risk groups.  
3. After a statin is started in an older adult, the **appropriateness of continued therapy** should be **reassessed frequently**.  
4. It is **reasonable to forgo initiating or to discontinue statin therapy** in patients with **functional decline, multiple comorbid conditions, frailty, or reduced life expectancy**.  
5. **Highâ€‘intensity statin therapy** is **rarely indicated** in patients **older than 75Â years** outside the **acute phase of acute coronary syndrome**.  
6. **Older adults** are **more likely** to experience **statinâ€‘associated muscle pain or weakness** and to have **drug interactions** with statins.  
7. A **coronary artery calcium (CAC) score** can help stratify risk in patients at **borderline or intermediate ASCVD risk** when deciding on statin therapy.  
8. In **select patients** with **persistently elevated triglyceride levels despite statin therapy**, particularly those with **established cardiovascular disease**, adding **icosapent ethyl** may lower cardiovascular event risk.  

#### ğŸ’¬ Extra  
1. *(Refers to StatementÂ 4)* Indicators of **frailty**, such as **weakness, unintentional weight loss, and impaired balance**, guide decisions to withdraw preventive medications like statins in older adults.  
2. *(Refers to StatementÂ 6)* Discontinuing unnecessary drugs can **reduce pill burden** and **decrease adverseâ€‘effect risk** in frail patients who take multiple medications.  

#### ğŸ·ï¸ Tags  
#Cardiology #AmbulatoryCare #PatientOver65 #Dyslipidemia #StatinTherapy #PrimaryPrevention #ASCVDRisk  

#### ğŸ“š Reference  
Oâ€™Malleyâ€¯PG, Arnoldâ€¯MJ, Kelleyâ€¯C, *etâ€¯al.* Management of dyslipidemia for cardiovascular disease risk reduction: synopsis of the 2020 updated U.S. Department of Veterans Affairs and U.S. Department of Defense clinical practice guideline. *Ann Intern Med.* 2020;173:822â€‘829. PMID:â€¯32956597  

#### ğŸ†” Question ID  
CVMCQ24032  

#### ğŸ•’ Last Updated  
FebruaryÂ 2025  

---  

#### ğŸ“– Related Text  
MKSAPÂ 19: CardiovascularÂ Medicine â€” Dyslipidemia, Management of Dyslipidemias, Management of Dyslipidemia in Special Populations  

### ğŸ“˜ Related Text Derivations  

#### âœ… True Statements  
1. Adults **older than 75Â years** without known ASCVD and an **LDL cholesterol level of 70Â mg/dL to 189Â mg/dL (1.81â€“4.90â€¯mmol/L)** may discuss the **potential benefits of statin therapy for primary prevention**.  
2. When statin therapy is chosen in this group, a **moderateâ€‘intensity statin** is recommended, and the **benefit is less robust** than in higherâ€‘risk populations.  
3. If the decision to start a statin is uncertain, measuring the **CAC score** is useful because **statin therapy can be avoided if the CAC score isâ€¯0**.  
4. It is **reasonable to forgo initiating or to discontinue statin therapy** in the presence of **functional decline, multiple comorbid conditions, frailty, or reduced life expectancy**.  
5. For **secondary prevention** in patients **older than 75â€¯years**, continuing a **moderateâ€‘intensity statin** is **beneficial and preferred** over highâ€‘intensity therapy in those already tolerating statins.  
6. **Initiating statin therapy** is **not recommended** in adults receiving **dialysis for endâ€‘stage kidney disease**, though **continuing an existing statin** may be reasonable.  
7. Counseling women about statins should account for **premature menopause** and **pregnancyâ€‘associated disorders** (hypertension, preeclampsia, gestational diabetes), which increase ASCVD risk.  
8. **Statins are contraindicated during pregnancy**; women of childâ€‘bearing age should use **reliable contraception** while on a statin and **stop therapy 1â€“2â€¯months before attempting pregnancy**.  
9. Patients with **HIV infection** have **increased coronary artery disease risk**; in such patients with lowâ€‘toâ€‘moderate ASCVD risk, **moderateâ€‘intensity pitavastatin** reduced cardiovascular events by **35â€¯% over 5â€¯years** compared with placebo.  
10. Patients with **rheumatoid arthritis** and other chronic inflammatory conditions have **increased cardiovascular risk**, but there are **no unique criteria** for initiating lipidâ€‘lowering therapy in these populations.  

#### ğŸ·ï¸ Tags  
#StatinTherapy #CACScore #PrimaryPrevention #SecondaryPrevention #ElderlyPatients #ChronicKidneyDisease #WomenHealth #HIV #InflammatoryDisease #Cardiology  

#### ğŸ“š Reference  
MKSAPÂ 19. CardiovascularÂ Medicine â€” Dyslipidemia, Management of Dyslipidemias, Management of Dyslipidemia in Special Populations. American College of Physicians.
